Kevin Michael Lundquist - 01 Sep 2026 Form 4 Insider Report for Outlook Therapeutics, Inc. (OTLK)

Reporting relationship: Chief Financial Officer
Issuer ticker: OTLK
Reported as of: 01 Sep 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Sep 2026, 16:32:01 UTC
Prior SEC filing: 01 Jul 2025
Source filing: View source filing
Reporting owner signature: /s/ Jennifer Couture, Attorney-in-Fact

Key filing fact

Kevin Michael Lundquist filed Form 4 for Outlook Therapeutics, Inc. (OTLK) on 02 Sep 2026.

Key facts

This page summarizes Kevin Michael Lundquist's Form 4 filing for Outlook Therapeutics, Inc. (OTLK).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 02 Sep 2026, 16:32.

Change

Previous filing in this sequence was filed on 01 Jul 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002074701 Primary reporting owner

Lundquist Kevin Michael

Relationship: Chief Financial Officer
Address: 111 SOUTH WOOD AVENUE, UNIT 100, ISELIN
Signature: /s/ Jennifer Couture, Attorney-in-Fact
Signature date: 02 Sep 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

OTLK transaction Derivative

Employee Stock Option (Right to Buy)

Award

Transaction value
Shares: +500,000
Change %
Price: $0.000000^*
Shares after: 500,000
Date: 01 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 500,000
Exercise price: $0.6300
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option was granted by Outlook Therapeutics, Inc. (the "Issuer") as an inducement material to the Reporting Person's entry into employment with the Issuer in accordance with Nasdaq Listing Rule 5635(c)(4). 25% of the shares subject to the option shall vest on September 1, 2027, with the remaining shares vesting in equal monthly installments over the following three years thereafter, subject to the Reporting Person's continuous service with the Issuer on each such date.